Federation Des Caisses Desjardins Du Quebec Krystal Biotech, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $18.9 Billion
- Q3 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 50 shares of KRYS stock, worth $7,645. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 50
-0.0%
Holding current value
$7,645
Previous $9,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
309Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$604 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$436 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$401 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$222 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$151 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.92B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...